E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the efficacy of palifermin administered at the dose of 180 mcg/kg IV for either 4 or 7 (additional 8th dose for subjects receiving boost radiation) weekly doses in reducing the incidence of severe [World Health Organization Grade 3 or 4] oral mucositis (OM) in locally advanced HNC subjects receiving RT with concurrent CT as adjuvant treatment for their disease (post-operative setting). |
|
E.2.2 | Secondary objectives of the trial |
To assess the safety and tolerability of palifermin at the dose of 180 mcg/kg IV in either 4 or 7 (additional 8th dose for subjects receiving boost radiation) weekly doses in this patient population.
To evaluate the effect of palifermin on the clinical sequelae of severe OM and on RT induced xerostomia in this patient population.
To evaluate long-term effects of palifermin on disease outcome and survival in this patient population. |
|
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
- Histologically documented squamous cell carcinoma. - Subjects with newly diagnosed (locally advanced) resected (R0, R1) HNC (American Joint Committee on Cancer [AJCC] Stage II, III, IVA, or IVB) involving either the oral cavity, oropharynx, nasopharynx, hypopharynx, or larynx and suitable to receive adjuvant concurrent RT/CT. - Radiation treatment field to receive planned dose of at least 50 Gy to areas of the oral cavity / oropharynx mucosa that can be visualized by non-instrumental oral inspection. - Subjects with larynx or hypopharynx tumors are eligible only if the radiation oncologist anticipates at least 2 of the 9 anatomical areas in the oral cavity [Mucositis Assessments] will receive a total dose of 50 Gy or more. - Signed informed consent. - Subject is 18 years of age or older. - ECOG performance status (PS) less than or equal to 2. - Planned interval < 6 calendar days between randomization and the first dose of RT.
Baseline laboratory assessments: - Hemoglobin (Hgb) more than or equal to 10g/dL - White blood count (WBC) > 3.5 x 10E9/L or - Absolute neutrophil count (ANC) > 1.5 x 10E9/L. - Platelet count more than or equal to 100 x 10E9/L. - Serum bilirubin less than or equal to 1.5 x institutional upper limits of normal (ULN). - Serum creatinine less than or equal to 2.0 mg/dL; Subjects with a serum creatinine more than or equal to 1.4 mg/dL and less than or equal to 2.0 mg/dL need to demonstrate a 24-hr urinary creatinine clearance more than or equal to 50 mL/min. - Serum or urine pregnancy test: Negative |
|
E.4 | Principal exclusion criteria |
- Tumors of the lips, paranasal sinuses, salivary glands, or of unknown primary tumors. - Metastatic disease (M1) / Stage IV C. - Presence or history of any other primary malignancy. - History of pancreatitis. - Prior radiotherapy to the site of disease. - Prior chemotherapy. - Other investigational procedures. - Thirty days or less since receiving an investigational product or device in another clinical trial. Current enrollment in another clinical trial is not permitted unless the sole purpose of the trial is for long-term follow-up/survival data. - Pregnant or breast-feeding women. - Refusal to use adequate contraceptive devices during treatment phase. - Known sensitivity to any of the products administered during dosing, including E coli-derived products. - Known to be sero-positive for human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV). - Previous treatment on this study or with other keratinocyte growth factors. - Compromised ability of the subject to give written informed consent and/or to comply with study procedures. - Refusal to give written informed consent to participate in this study and to sign the hospital information release form. - Unwilling or unable to complete the patient-reported outcome questionnaires. - Psychological, social, familial, or geographical reasons that would prevent regular follow-up. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary Efficacy Endpoint: - Incidence (%) of severe oral mucositis (Grades 3 or 4 on the WHO oral mucositis scale).
Secondary Efficacy Endpoints: - Duration of severe oral mucositis (WHO Grades 3 or 4). - Average daily patient-reported mouth and throat soreness score (as reported on the Oral Mucositis Weekly Questionnaire for Head and Neck Cancer [OMWQ-HN]) - Time to onset of severe oral mucositis (WHO Grades 3 or 4)· - Total dose of opioid analgesics used (mg of morphine equivalents)· - Incidence of unplanned breaks in RT more than or equal to 5 days (to include discontinuations of RT) - Incidence of unplanned breaks in CT more than or equal to 5 days (to include discontinuations of CT) - Incidence of xerostomia (CTCAE v3.0 Dry Mouth/Xerostomia scale Grade 2 or higher)
Safety Endpoints: Short-term - Incidence of adverse events and laboratory abnormalities using the CTCAE v.3.0 toxicity scales. - Incidence of serum anti-palifermin antibody formation. - Disease progression at week 12.
Safety Endpoints: Long-term - Time to disease progression. - Incidence of second primary tumors. - Incidence of other malignancies. - Progression-free survival (PFS). - Overall survival (OS). - Incidence of leukoplakia. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.6.13.1 | Other scope of the trial description |
NB. Pharmacogenetics additional only in subjects who sign a separate informed consent form. |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Week 12 is the last observation point. All subjects will be followed up until death, or lost to follow up, for long-term safety evaluation. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 0 |